Generics BulletinKorean biosimilars player Samsung Bioepis is to be spun out of its parent company Samsung Biologics into a new holding company, tentatively named Samsung Epis Holdings, in an effort to unlock value in
Pink SheetOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
ScripOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
ScripSouth Korean biopharma firms remained active participants in the recent J.P. Morgan Healthcare Conference in San Francisco, which came as the second Trump Administration assumed power in the US and a